Sandbox:DN: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__


{|class="wikitable" style="width:80%"
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Coronary angiography is indicated before valve intervention in patients with symptoms of angina, objective evidence of ischemia, decreased LV systolic function, history of CAD, or coronary risk factors (including men age >40 years and post- menopausal women).''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Coronary angiography should be performed as part of the evaluation of patients with chronic severe secondary MR.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|}
 
{|class="wikitable" style="width:80%"
|-
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Surgery without coronary angiography is reasonable for patients having emergency valve surgery for acute valve regurgitation, disease of the aortic sinuses or ascending aorta, or IE. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' It is reasonable to recommend an ICD for patients with HCM with:<nowiki>"</nowiki><br>'''a.'''  Sudden death presumably caused by HCM in 1 or more first-degree relatives<ref name="pmid21059440">{{cite journal |author=Bos JM, Maron BJ, Ackerman MJ, ''et al.'' |title=Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy |journal=Am. J. Cardiol. |volume=106 |issue=10 |pages=1481–6 |year=2010 |month=November |pmid=21059440 |doi=10.1016/j.amjcard.2010.06.077 |url=}}</ref>. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki><br>'''b.''' A maximum LV wall thickness greater than or equal to 30 mm<ref name="pmid11127463">{{cite journal |author=Elliott PM, Poloniecki J, Dickie S, ''et al.'' |title=Sudden death in hypertrophic cardiomyopathy: identification of high risk patients |journal=J. Am. Coll. Cardiol. |volume=36 |issue=7 |pages=2212–8 |year=2000 |month=December |pmid=11127463 |doi= |url=}}</ref><ref name="pmid11273061">{{cite journal |author=Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ |title=Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy |journal=Lancet |volume=357 |issue=9254 |pages=420–4 |year=2001 |month=February |pmid=11273061 |doi=10.1016/S0140-6736(00)04005-8 |url=}}</ref><ref name="pmid16762758">{{cite journal |author=Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ |title=Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy |journal=J Am Soc Echocardiogr |volume=19 |issue=6 |pages=788–95 |year=2006 |month=June |pmid=16762758 |doi=10.1016/j.echo.2006.01.005 |url=}}</ref><ref name="pmid10853000">{{cite journal |author=Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ |title=Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy |journal=N. Engl. J. Med. |volume=342 |issue=24 |pages=1778–85 |year=2000 |month=June |pmid=10853000 |doi=10.1056/NEJM200006153422403 |url=}}</ref>. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki><br>'''c.''' One or more recent, unexplained syncopal episodes<ref name="pmid19307481">{{cite journal |author=Spirito P, Autore C, Rapezzi C, ''et al.'' |title=Syncope and risk of sudden death in hypertrophic cardiomyopathy |journal=Circulation |volume=119 |issue=13 |pages=1703–10 |year=2009 |month=April |pmid=19307481 |doi=10.1161/CIRCULATIONAHA.108.798314 |url=}}</ref>. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' CT coronary angiography is reasonable to exclude the presence of significant obstructive CAD in selected patients with a low/ intermediate pretest probability of CAD. A positive coronary CT angiogram (the presence of any epicardial CAD) can be confirmed with invasive coronary angiography ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|-
|}
|}

Revision as of 20:26, 28 October 2016


Class IIa
"1. It is reasonable to recommend an ICD for patients with HCM with:"
a. Sudden death presumably caused by HCM in 1 or more first-degree relatives[1]. (Level of Evidence: C) "
b. A maximum LV wall thickness greater than or equal to 30 mm[2][3][4][5]. (Level of Evidence: C) "
c. One or more recent, unexplained syncopal episodes[6]. (Level of Evidence: C) "
  1. ↑ Bos JM, Maron BJ, Ackerman MJ; et al. (2010). "Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy". Am. J. Cardiol. 106 (10): 1481–6. doi:10.1016/j.amjcard.2010.06.077. PMID 21059440. Unknown parameter |month= ignored (help)
  2. ↑ Elliott PM, Poloniecki J, Dickie S; et al. (2000). "Sudden death in hypertrophic cardiomyopathy: identification of high risk patients". J. Am. Coll. Cardiol. 36 (7): 2212–8. PMID 11127463. Unknown parameter |month= ignored (help)
  3. ↑ Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ (2001). "Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy". Lancet. 357 (9254): 420–4. doi:10.1016/S0140-6736(00)04005-8. PMID 11273061. Unknown parameter |month= ignored (help)
  4. ↑ Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ (2006). "Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy". J Am Soc Echocardiogr. 19 (6): 788–95. doi:10.1016/j.echo.2006.01.005. PMID 16762758. Unknown parameter |month= ignored (help)
  5. ↑ Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ (2000). "Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy". N. Engl. J. Med. 342 (24): 1778–85. doi:10.1056/NEJM200006153422403. PMID 10853000. Unknown parameter |month= ignored (help)
  6. ↑ Spirito P, Autore C, Rapezzi C; et al. (2009). "Syncope and risk of sudden death in hypertrophic cardiomyopathy". Circulation. 119 (13): 1703–10. doi:10.1161/CIRCULATIONAHA.108.798314. PMID 19307481. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:DN&oldid=1264962"